| Note | |
| | |
| Entity | |
| Disease | Subset of multiple myeloma cell lines with t(11;14)(q13;q32). |
| Cytogenetics | MYEOV overexpression due to juxtaposition to the 5' enhancer or the most telomeric 3' enhancer of the immunoglobulin heavy chain (IgH). |
| | |
| | |
| Entity | 11q13 amplification and/or overexpression |
| Disease | Breast cancer; esophageal squamous cell carcinomas. |
| Prognosis | MYEOV DNA amplification correlated with estrogen and progesterone receptor-positive cancer, invasive lobular carcinoma type and axillary nodal involvement. In contrast to Cyclin D1 amplification, no association with disease outcome could be found. |
| | |
| | |
| Entity | Multiple myeloma |
| Prognosis | In a cohort of 171 myeloma patients, patients with MYEOVabsent MMC have an increased event-free survival compared to patients with MYEOVpresent MMC, after high-dose therapy and stem cell transplantation and a trend for increased overall survival. In a Cox proportional hazard model, MYEOV expression in MMC is predictive for event-free survival for patients independently of International Staging System stage, t(4;14) translocation, albumin, or B2M serum levels. In a second independent cohort of 208 patients (LR-TT3, from the University of Arkansas for Medical Sciences (Little Rock, AR, USA)), MYEOV had a "present" call in MMCs of 73% of patients. Patients with MYEOVabsent MMCs had a significant better overall survival in the LR-TT3 cohort. |
| Oncogenesis | In a cohort of 171 patients, MMC of 79% of the patients with newly diagnosed MM express MYEOV gene. A treatment with 5-aza-2'-deoxycytidine of 2 MYEOVabsent myeloma cell lines induced MYEOV expression without affecting that in the MYEOVpresent myeloma cells. MYEOV siRNA did not significantly induce apoptosis in myeloma cell lines, but it blocked the cell cycle entry into the S-phase. |
| | |
| | |
| Entity | Colon cancer |
| Oncogenesis | Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of colon cancer cell lines in vitro. Furthermore, in colon cancer, MYEOV stimulates colorectal cancer cell migration in vitro. MYEOV expression is enhanced by PGE2 treatment in colorectal cancer cells. |
| | |
| | |
| Entity | Gastric cancer |
| Oncogenesis | Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation and invasion of gastric cancer cells in vitro. |
| | |
| | |
| Entity | Neuroblastoma |
| Oncogenesis | MYEOV is a candidate gene target in neuroblastoma that was identified by chromosomal gain 11q13 through SNP analysis. MYEOV expression was analyzed in 55 neuroblastoma samples including 25 cell lines. MYEOV was shown to be upregulated in 11 out of 25 neuroblastoma cell lines and 7 out of 20 fresh tumors. Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of neuroblastoma cell line in vitro. |
| | |
| | |
| Entity | Oral squamous cell carcinoma |
| Oncogenesis | Gain of 11q13 was significantly associated with cervical lymph node metastasis in oral squamous cell carcinoma (54 patients included in the study). Copy number amplification of MYEOV is associated with cervical lymph node metastasis in oral squamous cell carcinoma. Lymph node metastasis is associated with a significant decrease of 5-years survival in oral squamous cell carcinoma. |
| | |
| MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. |
| Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J. |
| J Hum Genet. 2002;47(9):460-4. |
| PMID 12202983 |
| |
| MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2. |
| Lawlor G, Doran PP, MacMathuna P, Murray DW. |
| J Exp Clin Cancer Res. 2010 Jun 22;29:81. |
| PMID 20569498 |
| |
| Net1 and Myeov: computationally identified mediators of gastric cancer. |
| Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P. |
| Br J Cancer. 2006 Apr 24;94(8):1204-12. |
| PMID 16552434 |
| |
| MYEOV is a prognostic factor in multiple myeloma. |
| Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, Klein B. |
| Exp Hematol. 2010 Dec;38(12):1189-1198.e3. Epub 2010 Sep 18. |
| PMID 20854874 |
| |
| ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. |
| Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P. |
| Biochem Biophys Res Commun. 2006 Jun 23;345(1):216-21. Epub 2006 Apr 27. |
| PMID 16678123 |
| |
| Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma. |
| Sugahara K, Michikawa Y, Ishikawa K, Shoji Y, Iwakawa M, Shibahara T, Imai T. |
| Int J Oncol. 2011 Oct;39(4):761-9. doi: 10.3892/ijo.2011.1094. Epub 2011 Jun 22. |
| PMID 21701773 |
| |
| Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. |
| Takita J, Chen Y, Okubo J, Sanada M, Adachi M, Ohki K, Nishimura R, Hanada R, Igarashi T, Hayashi Y, Ogawa S. |
| Cancer Sci. 2011 Sep;102(9):1645-50. doi: 10.1111/j.1349-7006.2011.01995.x. Epub 2011 Jul 3. |
| PMID 21624008 |
| |
